Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01AIN
|
|||
| Former ID |
DND000032
|
|||
| Drug Name |
Fezakinumab
|
|||
| Synonyms |
Fezakinumab (IV), fezakinumab (SC), ILV-094 (IV), ILV-094 (SC), PF-5212367 (IV) PF-5212367(SC)
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Psoriasis vulgaris [ICD-11: EA90; ICD-9: 696] | Phase 2 | [1] | |
| Company |
Wyeth; pfizer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-22 (IL22) | Target Info | . | [2] |
| NetPath Pathway | IL9 Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01941537) Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis. U.S. National Institutes of Health. | |||
| REF 2 | Emerging Therapies for the Treatment of Psoriasis. Dermatol Ther (Heidelb) 2012 December; 2(1): 16. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.